Sanara MedTech Inc. Receives Innovative Technology Contract from Vizient for BIASURGE® Advanced Surgical Solution
Rhea-AI Summary
Sanara MedTech (Nasdaq: SMTI) announced that its BIASURGE® Advanced Surgical Solution received an Innovative Technology contract from Vizient, effective January 1, 2026. The contract followed recommendation by Vizient client-led hospital councils and provides Vizient members access to BIASURGE at pre-negotiated pricing and contracted terms. Vizient represents a broad client base with a portfolio exceeding $156 billion in annual purchasing volume. The company highlighted BIASURGE’s no-rinse irrigation and antimicrobial preservative as clinical differentiators and said it will engage Vizient clients to introduce the product and educate on surgical wound treatment potential.
Positive
- Innovative Technology contract awarded by Vizient, effective Jan 1, 2026
- Access to Vizient’s client network representing $156 billion in annual purchasing volume
- Contract provides pre-negotiated pricing and contracted terms for Vizient members
Negative
- Press release does not disclose any contract value or expected revenue impact
News Market Reaction
On the day this news was published, SMTI declined 1.97%, reflecting a mild negative market reaction. This price movement removed approximately $5M from the company's valuation, bringing the market cap to $227M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
SMTI gained 5.6% while peers were mixed: EMBC +7.09%, KMTS +4.42%, ANGO -8.99%, OSUR -1.2%, STXS -4.14%, pointing to a stock-specific reaction to the Vizient contract.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 10 | Product development update | Positive | +3.3% | OsStic™ progress update with strong preclinical data and launch timeline. |
| Nov 19 | Conference participation | Neutral | -8.8% | Announcement of presentation at Piper Sandler healthcare conference. |
| Nov 12 | Earnings release | Negative | -24.7% | Q3 2025 results with growth but large THP impairment and net loss. |
| Nov 11 | Strategic realignment | Negative | -0.4% | Decision to discontinue THP and refocus resources on surgical business. |
| Oct 01 | Earnings scheduling | Neutral | -2.9% | Scheduling and call details for upcoming Q3 2025 financial results. |
Recent history shows mixed reactions: positive technical/strategic news like product updates can lift shares, while earnings and strategic realignment headlines have often coincided with notable selloffs.
Over the last few months, SMTI has advanced its surgical-focused strategy. In Q3 2025, it reported strong revenue growth but large THP-related impairments and higher debt, and soon after announced discontinuation of Tissue Health Plus to focus on core surgical operations. OsStic™ progress in Dec 2025 was well received, while conference and earnings-related announcements sometimes saw sharp pullbacks. Today’s Vizient Innovative Technology contract for BIASURGE® fits the ongoing emphasis on surgical solutions and commercial access.
Market Pulse Summary
This announcement highlights an Innovative Technology contract from Vizient for BIASURGE®, effective January 1, 2026, giving SMTI contracted access to a large healthcare purchasing network with over $156 billion in annual volume. It reinforces the company’s strategic focus on surgical solutions following the discontinuation of THP. Investors may track subsequent adoption trends, inclusion in hospital purchasing pipelines, and how such contracts contribute to revenue growth alongside previously disclosed product development milestones.
Key Terms
innovative technology contract regulatory
no-rinse irrigation solution technical
antimicrobial preservative medical
broad-spectrum antimicrobial medical
AI-generated analysis. Not financial advice.
Contract awarded for products that bring improvement to the healthcare industry
FORT WORTH, TX, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara MedTech,” “Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, today announced that its BIASURGE® Advanced Surgical Solution (“BIASURGE”) product has received an Innovative Technology contract from Vizient® Inc. (“Vizient”), the nation’s largest provider-driven healthcare performance improvement company. The contract was awarded based on the recommendation of BIASURGE by hospital experts who serve on one of Vizient’s client-led councils, and it signifies to Vizient clients BIASURGE’s unique qualities that potentially bring improvement to the healthcare industry.
Innovative Technology contracts are recommended after review and interaction with products submitted through Vizient’s Innovative Technology Program. Vizient’s client-led councils identify technologies that have the potential to enhance clinical care, patient safety, healthcare worker safety or improve business operations of healthcare organizations.
“We are pleased to see Vizient award this new Innovative Technology contract for BIASURGE based on the recommendation of hospital experts, reflecting the differentiated nature of this surgical technology,” said Seth Yon, Sanara MedTech’s President and Chief Executive Officer. “BIASURGE’s no-rinse irrigation solution enables surgeons to cleanse the wound bed more efficiently than with saline alone, and its antimicrobial preservative provides broad-spectrum antimicrobial effectiveness in the irrigation solution.”
Mr. Yon continued, “Importantly, this new Innovative Technology contract offers Vizient’s extensive network of healthcare facility customers with access to BIASURGE at contracted pricing and pre-negotiated terms, effective January 1, 2026. We look forward to engaging with Vizient’s clients to introduce BIASURGE and educate them on its potential to improve the treatment of surgical wounds.”
“After a review of BIASURGE®, Vizient’s client-led council agreed this technology offers a unique benefit over other products available in the market today and recommended it for an Innovative Technology contract. We are pleased to award this new contract to Sanara,” said Kelly Flaharty, Associate Vice President, Contract Operations for Vizient.
Vizient represents a diverse client base that includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute healthcare providers and has a portfolio that represents more than
About BIASURGE® Advanced Surgical Solution
BIASURGE Advanced Surgical Solution is a no-rinse irrigation solution designed to deliver more efficient surgical cleansing. In the solution, an antimicrobial preservative provides broad-spectrum effectiveness against pathogenic microorganisms. Indicated for mechanical cleansing and removal of debris—including microorganisms—from surgical wounds, BIASURGE’s proprietary formulation leverages synergistic technology. Optimized for pH, viscosity, and osmolality, BIASURGE is designed to ensure maximum performance while maintaining safety and effectiveness and is suitable for use with irrigation systems.
Specifically designed to address the demands of complex surgical scenarios, BIASURGE was developed to enhance surgical precision and visibility by maintaining a cleaner operative field during use. Its mechanical cleansing action supports infection-control strategies, demonstrating how intentional, purpose-driven design can deliver superior performance and contribute to improved surgical outcomes.
About Sanara MedTech Inc.
Sanara MedTech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. The Company develops, markets and distributes surgical products for use by physicians and clinicians in hospitals. Each of the Company’s products, services, and technologies are designed to achieve the goal of providing better clinical outcomes at a lower overall cost for patients. Sanara’s products are primarily sold in the North American surgical tissue repair markets. Sanara markets and distributes CellerateRX® Surgical Activated Collagen® Powder, BIASURGE® Advanced Surgical Solution, FORTIFY TRG® Tissue Repair Graft, FORTIFY FLOWABLE® Extracellular Matrix, as well as a portfolio of advanced biologic products including: ACTIGEN® Verified Inductive Bone Matrix, ALLOCYTE® Plus Advanced Viable Bone Matrix, BiFORM® Bioactive Moldable Matrix, and TEXAGEN® Amniotic Membrane Allograft to the surgical market. The Company believes it can drive its pipeline from concept to preclinical and clinical development while meeting quality and regulatory requirements. The Company strives to be one of the most innovative and comprehensive providers of effective surgical solutions and is continually seeking to expand its offerings for patients requiring treatments in the United States. For more information, please visit SanaraMedTech.com.
Information about Forward-Looking Statements
The statements in this press release that do not constitute historical facts are “forward-looking statements,” within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. These statements may be identified by terms such as “aims,” “anticipates,” “believes,” contemplates,” “continue,” “could,” “estimates,” “expect,” “forecast,” “guidance,” “intends,” “may,” “plans,” “possible,” “potential,” “predicts,” “preliminary,” “projects,” “seeks,” “should,” “targets,” “will” or “would,” or the negatives of these terms, variations of these terms or other similar expressions. These forward-looking statements include, among others, statements regarding the efficacy of BIASURGE, the potential sale of BIASURGE to Vizient clients upon award of the Innovative Technology contract, the Company’s ability to improve its operating efficiency, the Company’s business strategy and mission, the development of new products, the timing of commercialization of the Company’s products, and the regulatory approval process. These items involve risks, contingencies and uncertainties such as uncertainties associated with the development and process for obtaining regulatory approval for new products, the Company’s ability to build out its executive team, the Company’s ability to identify and effectively utilize the net proceeds of its term loan to support the Company’s growth initiatives, the extent of product demand, market and customer acceptance, including through the Vizient portfolio, the effect of economic conditions, competition, pricing, uncertainties associated with the development and process for obtaining regulatory approval for new products, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company’s SEC filings, which could cause the Company’s actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements.
All forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to revise any of these statements to reflect future circumstances or the occurrence of unanticipated events, except as required by applicable securities laws.
Investor Relations Contact:
Jack Powell or Mike Piccinino, CFA
ICR Healthcare
IR@sanaramedtech.com
FAQ
What did Sanara MedTech (SMTI) announce on January 7, 2026 regarding Vizient?
How does the Vizient contract affect access to BIASURGE for hospitals and health systems?
Why did Vizient award an Innovative Technology contract to BIASURGE (SMTI)?
When does the Vizient Innovative Technology contract for BIASURGE become effective for SMTI?
Does the Sanara MedTech press release disclose the financial value of the Vizient contract?
